1. Home
  2. IMMP vs GNS Comparison

IMMP vs GNS Comparison

Compare IMMP & GNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immutep Limited

IMMP

Immutep Limited

N/A

Current Price

$3.05

Market Cap

31.5M

Sector

Health Care

ML Signal

N/A

Logo Genius Group Limited

GNS

Genius Group Limited

N/A

Current Price

$0.12

Market Cap

32.1M

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
IMMP
GNS
Founded
1987
2002
Country
Australia
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
31.5M
32.1M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
IMMP
GNS
Price
$3.05
$0.12
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
17.0K
★ 5.3M
Earning Date
09-01-2026
09-28-2026
Dividend Yield
N/A
★ 155.52%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$127.02
Revenue Next Year
N/A
$36.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$0.12
52 Week High
$5.36
$1.06

Technical Indicators

Market Signals
Indicator
IMMP
GNS
Relative Strength Index (RSI) 53.33 37.29
Support Level $3.06 $0.12
Resistance Level $3.23 $0.14
Average True Range (ATR) 0.23 0.01
MACD -0.14 -0.00
Stochastic Oscillator 7.58 6.18

Price Performance

Historical Comparison
IMMP
GNS

About IMMP Immutep Limited

Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

About GNS Genius Group Limited

Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. Its revenue is derived from five reportable segments: Central, Academy, School, Resorts, and Discontinued operations. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America.

Share on Social Networks: